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Background: In settings where multiple HIV prevention trials are conducted in close proximity,
trial participants may attempt to enroll in more than one trial simultaneously. Co-enrollment
impacts on participant's safety and validity of trial results. We describe our experience,
remedial action taken, inter-organizational collaboration and lessons learnt following the
identification of co-enrolled participants.
Experiences: Between February and April 2008, we identified 185 of the 398 enrolled participants
as ineligible. In violation of the study protocol exclusion criteria, there was simultaneous
enrollment in another HIV prevention trial (ineligible co-enrolled, n=135), and enrollment of
women who had participated in a microbicide trial within the past 12 months (ineligible not co-
enrolled, n=50). Following a complete audit of all enrolled participants, ineligible participants
were discontinued via study exit visits from trial follow-up. Custom-designed education program
on co-enrollment impacting on participants' safety and validity of the trial results was
implemented. Shared electronic database between research units was established to enable
veriﬁcation of each volunteer's trial participation and to prevent future co-enrollments.
Lessons learnt: Interviews with ineligible enrolled women revealed that high-quality care,
financial incentives, altruistic motives, preference for sex with gel, wanting to increase their
likelihood of receiving active gel, perceived low risk of discovery and peer pressure are the
reasons for their enrollment in the CAPRISA 004 trial.
Conclusion: Instituting education programs based on the reasons reported by women for seeking
enrollment in more than one trial and using a shared central database system to identify co-
enrollments have effectively prevented further co-enrollments.






Sub-Saharan Africa continues to experience high HIV
incidence rates [1], and is therefore an important region for
carrying out HIV prevention trials in order to test potential
biomedical interventions to curb the current pandemic [2]. A
systematic review of 37 HIV prevention randomized control
trials (RCTs) showed that approximately 90% demonstrated
no signiﬁcant effects on HIV incidence [3]. Reasons for these
results could be a failure in the underlying conceptualization
of the intervention, an ineffective intervention, provision of
enhanced prevention packages in the comparison arm or
failure to monitor and correct shortcomings in trial imple-
mentation [2,3].
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Nevertheless, RCTs are the gold standard for evaluating
the effectiveness of an intervention [3] and provide data on
the appropriateness and feasibility of the intervention, upon
which clinical practices can be based. The strict eligibility
criteria may limit the external validity and generalizability of
the ﬁndings, yet the scientiﬁc integrity of the RCT in its
inherent design minimizes the effects of confounding vari-
ables with each participant having the same chance of
receiving a test intervention and both measured and
unmeasured confounding variables are considered to be
equally distributed amongst the study arms [4].
Almost 15,000 women in sub-Saharan Africa have partic-
ipated in HIV prevention trials. The trial sites are usually
geographically isolated, and participants are recruited from
separate communities or catchment areas [5–10]. However,
with increasing numbers of interventions tested in parallel
such as microbicides, vaccines, cervical barriers, and struc-
tural changes, geographic isolation of trial sites is no longer
guaranteed, making it possible for trial participants to
participate in more than one trial simultaneously. There are
many reports on factors that motivate volunteers to partic-
ipate in clinical trials [11–13] but little attention has been
paid to the reasons for co-enrollment or participation in
multiple trials simultaneously [11,14]. Key elements of
research participation are governed by human subject
research protection of respect, beneﬁcence, and justice and
to preserve scientiﬁc integrity and to maintain the safety of
trial participants.
This paper describes the identiﬁcation of the co-enroll-
ment of participants in the CAPRISA 004 Tenofovir gel and
other HIV prevention trials, steps taken to rectify the
problem, implementation of inter-organizational collabora-
tion to prevent recurrences and lessons learnt.
2. Experiences
2.1. CAPRISA 004 Tenofovir gel trial
CAPRISA 004 was a Phase IIb double-blind RCT designed to
establish the safety and effectiveness of 1% Tenofovir gel in
preventing HIV infection in women in South Africa (CAPRISA
004 trial) [9]. The trial was conducted at two CAPRISA clinics;
the urban CAPRISA eThekwini Clinic in the central business
district of Durban and the rural Vulindlela Clinic, 150 km inland
from Durban. The trial was initiated in May 2007 with an
enrollment target of 920 participants. During cohort accrual for
CAPRISA 004 at the urban and rural clinics, another research
organization had several active HIV prevention trials underway
in the greaterDurban area (Fig. 1), at sites a substantial distance
away from the CAPRISA urban clinic.
Recruitment strategies at the urban clinic initially targeted
women attending the adjacent local sexually transmitted
disease (STD) clinic; self-identiﬁed sex workers from sur-
rounding areas and women transitioning from two other
CAPRISA cohort studies [15,16]. However, enrollment was
also open to women from the general population.
During the planning of the CAPRISA 004 trial, the potential
for co-enrollment was considered as a cellulose sulphate
microbicide trial site was within 5 km of the urban site
(Fig. 1). Initial concern about co-enrollment dissipated when
the cellulose sulphate trial closed several months premature-
ly before the CAPRISA 004 trial commenced.
Fig. 1. HIV prevention trial sites in the greater Durban area, KwaZulu-Natal, South Africa.
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Even though a key exclusion criterion included self-report of
current enrollment in any other HIV prevention trial, or
participation in such a trial within the past 12 months, we
made three assumptions about co-enrollment:
• Following the premature closure of the cellulose-sulphate
trial, the distance between the urban site and the closest
other microbicide trial site was 25 km away. We assumed
that participants would not travel this distance to partic-
ipate simultaneously in another clinical trial.
• The primary recruitment was done through the STD clinic
which was not a recruitment site for other organizations
conducting HIV prevention trials. We assumed that there
would be no overlap with recruitment.
• The trial site staff were conﬁdent that self-report of current
or recent non-participation in another trial of vaginally
applied product or behavioural study would be reliable. We
assumed that participants would be honest in their
responses.
This false sense of security meant that there were no
additional systems in place to verify self-reports and identify
co-enrolled participants.
2.2. Discovery of co-enrolled trial participants
Two distinct incidents led to the discovery of co-
enrollment. Early in February 2008, a research nurse review-
ing participant family planning cards identiﬁed two partici-
pants who disclosed that they were currently participating in
another microbicide trial. At about the same time during a
studymonitoring visit, a monitor identiﬁed amongst returned
study applicators a study applicator from anothermicrobicide
trial. Pharmacy staff who subsequently instituted more
rigorous review of used applicators found another participant
returning applicators from another trial.
A full audit was launched at both CAPRISA sites and the
extent of co-enrollment was established by April 2008 as
conﬁned to the CAPRISA urban clinic. Three categories of trial
participants were identiﬁed:
• Ineligible co-enrolled: participants who were participating
in two HIV prevention trials simultaneously. These partici-
pants were participating in a trial of a vaginally applied
product or behaviour modiﬁcation for HIV prevention ﬁrst
and then enrolled in CAPRISA 004 trial.
• Ineligible not co-enrolled: participants enrolled in CAPRISA
004 trial only, but who had participated in a trial of a
vaginally applied product within the last 12 months.
• Eligible enrolled: participants who met all the eligibility
criteria for enrollment into CAPRISA 004 trial.
At the CAPRISA urban clinic, 185 of the 398 enrolled
participants were either ineligible co-enrolled (n=135) or
were ineligible not co-enrolled (n=50). As these participants
did not meet the pre-randomization criteria, they were
terminated from CAPRISA 004.
A further 4 participants were found to have enrolled in
another microbicide trial after they had enrolled in CAPRISA
004 trial. Since these participants met the eligibility criteria at
the time of enrollment, their participation in the CAPRISA 004
trial was continued subject to their termination in the other
trials.
Following the unblinding of the treatment allocation on
study completion in June 2010, it was established that of the
185 ineligible participants, 94 (50.8%) were assigned to the
tenofovir arm and 91 (49.2%) to the placebo arm. Of the 889
eligible participants included in the primary intent to treat
analysis for CAPRISA 004 [9], ineligible participants were
older, had a lower monthly income, had a greater mean
parity, reported having more sex and more condom use with
sex and had fewer adverse events reported (all pb0.001)
compared to eligible participants (Table 1). We found no
differences in the primary outcome of HIV infection or
secondary outcome of pregnancy rates (Table 1).
2.3. Communication with key stake holders
A full audit was completed within three weeks of the co-
enrollment discovery and several consultations were held
between CAPRISA and neighbouring AIDS research unit. The
CAPRISA 004 Data Safety and Monitoring Board (DSMB) and
regulatory authorities such as the University of KwaZulu-
Natal Biomedical Research Ethics Committee (BREC), Family
Health International Protection of Human Subjects Commit-
tee (FHI-PHSC), and the South African Medicines Control
Council (MCC) were notiﬁed. In addition, other groups
conducting researchwithin a 100 km radius, local community
groups, advocacy organizations, the CAPRISA Research Sup-
port Groups and CAPRISA's community liaison teamwere also
notiﬁed. Early in May 2008 the Microbicides Trial Network
released a statement on the ineligible participants enrolled in
the CAPRISA 004 trial [17].
Based on the International Conference on Harmonization
(ICH) guidelines E9 on inclusion and exclusion criteria [18]
and in consultation with the study statisticians and the DSMB
the Principal investigators took the decision, to withdraw all
participants identiﬁed as ineligible and enrolled in the
CAPRISA 004 trial. Study staff, site staff and all trial
participants were informed on the decision and all ineligible
enrolled participants were terminated from CAPRISA 004.
The DSMB additionally recommended that the trial
continue and advised the study team to:
• Retain women who enrolled in another study after
enrolling in the CAPRISA 004 trial (n=4).
• Take appropriate measures to achieve study objectives in
the shortest amount of time by increasing the sample size to
replace participants who had been terminated.
• Observe standard exit procedures for ineligible enrolled
participants being withdrawn, including safety assessment.
• Report to the DSMB on co-enrollments at subsequent
meetings, including whether or not there were more
attempts at co-enrollment and/or the number of co-
enrollments averted.
3. Lessons learnt
3.1. Changes in study procedures
A number of innovative measures were developed to
remove the possibility of further co-enrollments. Firstly,
study staff completed training to understand the disadvan-
tages of co-enrollments and screening for co-enrollments
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and to be vigilant during participant study visits. Participant
scripts were created to ensure that the concept of co-
enrollment was reinforced during all information and
informed consent sessions and at all study visits. It was
critically important that participants understood the con-
sequences of co-enrollments especially in trials of investi-
gational products to potentially endanger their safety,
confound safety monitoring of individual participants and
compromise the scientiﬁc integrity of all studies that the
participant enrolled in. Furthermore, additional counselling
was instituted to ensure that eligible enrolled participants
understood the risks of co-enrolling and did not enroll in
other trials during the course of their participation in
CAPRISA 004 trial.
Study related information material used at screening,
enrollment informed consent formsweremodiﬁed to provide
explicit information of the dangers of co-enrollment. Partici-
pants signed a declaration in the informed consent conﬁrm-
ing that they were not enrolled in another study of an
investigational drug. We administered a structured question-
naire to assess co-enrollment in all participants. All revised
documents and informed consents were approved by BREC
prior to administration.
Importantly, the neighbouring AIDS research unit gener-
ously modiﬁed and shared its existing participant database
with CAPRISA for conﬁrming the unique South African
identiﬁcation numbers (SA ID) using a secured password
protected and restricted user access electronic database. The
use of this shared database for checking of SA IDs of CAPRISA
004 volunteers to verify if theywere currently participating in
any other trial that was testing an investigational product was
approved by UKZN BREC. No other study related personal or
other information was shared between studies and organiza-
tions. The database was accessed through a common server
and included a complete listing of HIV prevention studies
being conducted in this region. The database included
sections specifying date of enrollment and exit date from
the speciﬁc study to determine if the potential participant has
been enrolled in any of the existing studies in this shared
database. If a volunteer was identiﬁed as already participating
in a study of an investigational product she would be
informed accordingly and all further pre-enrollment proce-
dures were halted and the volunteer classiﬁed as ineligible
based on the exclusionary criteria.
The CAPRISA pharmacy maintains an audit trail in gel
dispensing, veriﬁcation of gel variant allocation and the
return of used and unused applicators at each monthly visit.
Whilst these measures had been set up to ensure the
availability of good quality product at all times and to assist
with enhancing measures of adherence, the pharmacy
procedures also identiﬁed a gel applicator from another trial
returned erroneously as a CAPRISA 004 applicator. The high
Table 1
Comparison of characteristics of CAPRISA 004 ineligible (co-enrolled and not co-enrolled) and eligible trial participants (N=1074).
Characteristics Ineligible co-enrolled and





Mean age 25.6 years 23.9 years b0.001
High school education completed or more 88 (47%) 365 (41%) 0.120
Monthly incomebR1000 140 (75.7%) 718 (80.8%) 0.001
Married 13 (7.0%) 50 (5.6%) 0.491
Stable partner 153 (82.7%) 783 (88.1%) 0.053
Mean parity 1.5 1.1 b0.001
Baseline sexual behaviour
Mean age sexual debut 17.7 years 17.4 years 0.093
Mean number of lifetime sexual partners 3.8 3.3 0.548
Mean age of oldest partner in the last 30 days 30.0 years 27.4 years b0.001
Reported sex in the past 7 days 155 (83.8%) 550 (61.9%) b0.001
Always use condom during sex 84 (45.4%) 259 (29.1%) b0.001
Anal sex in the past 30 days 0 (0.0%) 4 (0.4%) 1.000
New sex partners in the past 30 days 5 (2.7%) 10 (1.1%) 0.160
Sex partners had other sex partners in the past 30 days 33 (17.8%) 179 (20.1%) 0.591
More than 2 casual sex partners in the past 30 days 5 (2.7%) 20 (2.2%) 0.788
Ever forced to have sex with anyone 2 (1.1%) 6 (0.7%) 0.632
Ever received money in exchange for sex 5 (2.7%) 17 (1.9%) 0.565
Knows sex partner had an HIV test in the last 30 days 4 (2.2%) 19 (2.1%) 0.188
Alcohol consumed before last sex 6 (3.2%) 38 (4.3%) 0.684
Genital signs and symptoms in the past 30 days 65 (35.1%) 335 (37.7%) 0.559
Study arm allocation
Tenofovir gel 94 (50.8%) 445 (50.1%) 0.872
Placebo 91 (49.2%) 444 (49.9%)
Primary endpoint
HIV incidence/100 women years (95% CI ) 6.5 (2.1–15.1) 7.3 (5.9–8.9) 0.637
Secondary endpoints
Adverse events/participant 155/89 (48.1%) 4692/838 (94.3%) b0.001
Serious adverse events/participant 3/3 (1.6%) 39/37 (4.2%) 0.132
Pregnancy incidence/100 women years (95% CI) 5.1 (1.4–13.2) 4.0 (3.0–5.2) 0.786
a Ineligible co-enrolled: participants who were participating in two HIV prevention trials simultaneously. Ineligible not co-enrolled: participants who had
participated in a trial of a vaginally applied product within the last 12 months.
b Eligible enrolled: participants who met all the eligibility criteria for enrollment into CAPRISA 004 trial.
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level of vigilance from pharmacy staff was an important
ongoing adjunct to the linked database.
3.2. Greater awareness of recruitment populations
Whilst the priority population for the urban CAPRISA
Clinic site was the STD clinic, community recruitment and
community volunteers were allowed. As the CAPRISA 004
protocol allowed for transitioning of participants from other
CAPRISA cohort studies with no investigational product,
CAPRISA 004 recruitment staff incorrectly assumed that
prior participation in trials of investigational drugs or
behaviour modiﬁcation for HIV prevention was also accept-
able. Additionally the screening process did not provide
sufﬁcient information on the risks associated with simulta-
neous use of multiple investigational products through
participation in multiple trials.
3.3. Participant-related factors that contributed to co-
enrollment
Whilst every effort was made to ensure that volunteers
understood trial-related procedures and the implication of
trial participation, understanding why people join trials is
important. Following individual interviews (n=13) and
focus group discussions (n=2) with site staff and exit
interviews conducted with co-enrolled participants, key
themes emerged as contributory to participant's seeking
enrollment in multiple trials.
3.3.1. High-quality health care as an incentive
Whilst public sector primary health care services provide
free contraceptives, HIV testing services and treatment for
sexually transmitted infections at no cost, under-developed
health facilities, overworked staff and drug shortages are a
reality that impact access to and quality of health services for
indigent populations. The high quality care with emphasis on
attention to detail in the trial was an important beneﬁt
women were unwilling to lose once their follow-up in a
particular trial ended.
3.3.2. Financial incentive
Some of the research participants were unemployed or if
employed, had low earning capacity. For some of the women
who had little or no income, the amount of R150 per study
visit that was speciﬁed by the government regulatory body,
the Medicines Control Council, was sufﬁcient incentive for
study participation [19,20]. As multiple trial sites arise within
deﬁned geographical areas, a network of astute research
participants can keep each other informed of clinical trial
opportunities, with some participants even acting as self-
appointed recruiters providing information on where clinical
trials are actively enrolling. Women co-enrolling in multiple
trials can skillfully respond to questions to avoid being
identiﬁed as co-enrollees, and some have even worked out
ways of reducing study visit time.
3.3.3. Altruism
Many participants came from communities being devas-
tated by the HIV/AIDS epidemic, and some felt a strong
imperative to contribute to ﬁnding solutions to the epidemic.
The women were able to articulate their altruistic motivation
for trial participation and their tangible need to contribute to
the urgent need to ﬁnd options for women. For them clinical
trial participation provided an opportunity to contribute to
ﬁnding options to prevent HIV infection in women, and they
felt that they were making a contribution through their
participation.
3.3.4. Seeking gel for a better sex life
Some women mentioned that their sexual experiences
had improved since initiating gel use. Some women, who
knew that the trial they were in would be ending soon. learnt
about the CAPRISA 004 trial and joined it to be able to
continue with gel use. Some women said that they wanted to
co-enroll because they felt that this could increase their
chances of getting an active product instead of the placebo.
3.3.5. Low risk of discovery and peer pressure
Some women knew that others had successfully co-
enrolled without being identiﬁed. Furthermore, these
women were aware that trial staff had no way of knowing
whether they used the study product or not, and elected not
to use any trial study product. They rationalized that they
were not increasing their personal risk in any way because
they were not using any product, were attending study visits
and undergoing study procedures.
Many women understood that their participation in the
other trials they were already enrolled in was coming to an
end and that overlaps between the two trials were minimal
and worth the risk and effort to secure high quality care,
income or access to study gel that they had become
accustomed to. Some mentioned peer-pressure from fellow
co-enrollees as a reason for their co-enrollment. Importantly,
most co-enrolled participants knew that they were doing
something that was not allowed.
4. Conclusions
Participation in HIV prevention trials is often time
consuming and involves commitment by participants to
make multiple visits, endure clinical procedures and adhere
to the investigational product regimen. However, women are
ﬁnancially reimbursed and provided with quality care at the
trial sites such as access to family planning, treatment of
sexually transmitted infections, access to caring clinicians,
and appropriate counselling and referrals. Signiﬁcantly the
majority of study participants were honest in their self-report
on non-enrollment in other studies of investigational drugs.
Co-enrollment has important implications for both the
trial participants and the integrity of the trial. Clinically,
exposure to more than one investigational product poses
safety concerns for the participants, and it becomes impos-
sible to attribute adverse events to one or another trial
product. Scientiﬁcally, co-enrollment may attenuate or
synergize the impact of a trial product and invalidate the
measure of effect. Although participants are made aware of
the potential dangers of co-enrollment during the informed
consent process, this was insufﬁcient to prevent co-enroll-
ment in the CAPRISA 004 trial.
Women attending a study clinic have many opportunities
to share information with each other and proximate clinical
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trial sites incubate such networking.Womenwho co-enrolled
generally did so intentionally and for a number of very
rational reasons. The study team had to react quickly and
decisively to disqualify co-enrollees and preclude future
ineligible enrollments in the CAPRISA 004 trial.
The likelihood of co-enrollment was not fully appreciated
by study staff prior to inception, and systems for identifying
and preventing ineligible enrollment were poorly developed.
The importance of a database system shared amongst nearby
research organizations is now apparent, and is a prominent
part of planning any future trials in Durban.
As South Africa will continue to host large-scale HIV
prevention trials, collegial inter-organizational collaboration
will be necessary to eliminate co-enrollment. Shared regis-
tries are essential to protect the safety of trial participants and
validity of these vital studies.
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